Research Papers:

Asymptomatic hyperuricemia and coronary artery disease in elderly patients without comorbidities

Junnan Wu, Guangtao Lei, Xiao Wang, Yuezhong Tang, Huan Cheng, Guihua Jian, Xianfeng Wu and Niansong Wang _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:80688-80699. https://doi.org/10.18632/oncotarget.21079

Metrics: PDF 1584 views  |   HTML 2758 views  |   ?  


Junnan Wu1,*, Guangtao Lei2,*, Xiao Wang3, Yuezhong Tang4, Huan Cheng4, Guihua Jian1, Xianfeng Wu1 and Niansong Wang1

1Department of Nephrology, Affiliated Sixth People's Hospital, Shanghai Jiao Tong University, Shanghai, China

2Department of Cardiology, The Second Affiliated Hospital of Nanchang University, Nanchang, China

3Department of Endocrinology, Affiliated Sixth People's Hospital, Shanghai Jiao Tong University, Shanghai, China

4Kangjian Community Health Center, Xuhui District, Shanghai, China

*These authors contributed equally to this work

Correspondence to:

Niansong Wang, email: [email protected]

Xianfeng Wu, email: [email protected]

Keywords: comorbidities, coronary artery disease, elderly, hyperuricemia, serum uric acid

Received: July 03, 2017     Accepted: September 03, 2017     Published: September 19, 2017


Because many subjects with hyperuricemia have comorbidities, it can be difficult to differentiate the role of hyperuricemia from that of other comorbidities of coronary artery disease (CAD). Subjects aged ≥ 65 years were enrolled in the study and were available at enrollment and at 5-year follow-up. Subjects were excluded if they were overweight or obese, hypertensive, diabetic, hyperlipidemic, had a pre-existing cardiovascular disease, a history of gout or hyperuricemia on medications, or chronic kidney disease as estimated by a glomerular filtration rate (eGFR) < 60 mL/min per 1.73 m2. We used Poisson regression to estimate the hazard ratio (HR) for incident CAD events between hyperuricemic (> 7 mg/dL in men and ≥ 6 mg/dL in women) and normouricemic subjects. A total of 2,142 subjects without comorbidities (mean age of 70.7 ± 5.9 years, 1,194 men) were followed for 57.4 ± 8.9 months. Hyperuricemia was associated with an increased cumulative incidence of incident CAD events (15.0% versus 8.8%, P < 0.001). After adjusting for confounding factors, hyperuricemia independently predicted the risk of incident CAD events (HR=1.71, 95% CI 1.26–2.34). In conclusion, asymptomatic hyperuricemia is a valuable biomarker for predicting the development of incident CAD events.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21079